Table 3 HLA-B*5701 prevalence studies conducted in different regions across the world
From: HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
Country, publication year | Number of subjects | Prevalence | HLA-B*5701 screening recommendation | Reference |
|---|---|---|---|---|
Australia, 2006 | 260 | 7.7% | Yes | [15] |
Taiwan, 2007 | 320 | 0.3% | No | [18] |
19 countries, 2008 | 1956 | 5.6% | Yes | [14] |
Chile, 2010 | 492 | 2.2% | Yes | [23] |
México, 2011 | 300 | 2% | Yes | [24] |
Brazil, 2011 | 96 | 3.1% | Yes | [26] |
Brazil, 2014 | 517 | 5.6% | Yes | [12] |
Costa Rica, 2014 | 200 | 5% | Yes | [25] |
Argentina, 2015 | 1646 | 4.9% | Yes | [27] |
Iran, 2016 | 198 | 3% | HLA-B*5701 may reduce risk, but there are cost issues | [22] |
USA, 2017 | 385 | 3.4% | Yes | [21] |